Effects of Periprocedural Tirofiban vs. Oral Antiplatelet Drug Therapy on Posterior Circulation Infarction in Patients With Acute Intracranial Atherosclerosis-Related Vertebrobasilar Artery Occlusion [PDF]
Frontiers in Neurology, 2020 Background and purpose: Tirofiban and oral antiplatelet drugs can be used to inhibit reocclusion and restore microvascular reperfusion during endovascular treatment (EVT).
Xuan Sun +5 more
doaj +2 more sources
Influence of Tirofiban maintenance duration on patients with acute myocardial infarction treated by percutaneous coronary intervention [PDF]
Chronic Diseases and Translational Medicine, 2015 Objective: To evaluate the efficacy and short term prognosis of Tirofiban in different treatment duration in patients with acute ST segment elevation myocardial infarction (STEMI) and percutaneous coronary intervention (PCI) combined with intracoronary ...
Zhen-Guo Ji +6 more
doaj +2 more sources
Influence of tirofiban on stroke outcome after mechanical thrombectomy in acute vertebrobasilar artery occlusion [PDF]
BMC Neurology, 2022 Background Even undergoing mechanical thrombectomy (MT), patients with acute vertebrobasilar artery occlusion (AVBAO) still have a high rate of mortality.
Xiding Pan +6 more
doaj +2 more sources
Mechanical Solitaire Thrombectomy with Low-Dose Booster Tirofiban Injection [PDF]
Neurointervention, 2016 PurposeMechanical thrombectomy using a Solitaire stent has been associated with a high recanalization rate and favorable clinical outcome in intra-arterial thrombolysis.
Duck-Ho Goh +3 more
doaj +3 more sources
Tirofiban for Preventing Early Neurological Deterioration in Acute Ischemic Stroke Within 48 Hours of Onset: Evidence From a Dual-Method Analysis Using Propensity Score Matching and Multivariable Regression. [PDF]
CNS Neurosci TherPrevious studies have shown that tirofiban may reduce the risk of early neurological deterioration within 24 h after symptom onset in patients with acute ischemic stroke (AIS). However, evidence on its efficacy beyond this time window is limited. This study suggests that tirofiban may still confer potential therapeutic benefits in AIS patients without ...
Wen Q +13 more
europepmc +2 more sources
Efficacy of Tirofiban combined with oral antiplatelet therapy in progressive ischemic stroke: A systematic review and meta-analysis. [PDF]
Exp Ther MedYu Y, Deng T, Jiang Y, Ge J, Li Y.
europepmc +3 more sources
Blood Pressure Variability and 90-Day Functional Outcome in Branch Atheromatous Disease-Related Stroke: A Multicenter Prospective Study. [PDF]
J Clin Hypertens (Greenwich)ABSTRACT Branch atheromatous disease (BAD)‐related stroke shows distinct prognostic features from other stroke subtypes, with modifiable prognostic factors remaining inconclusive. The present research investigated the association between systolic blood pressure variability (BPV) and 90‐day functional outcomes of BAD‐related stroke.
Zhou Y +7 more
europepmc +2 more sources
Frontiers in Neurology, 2021 Objective: To evaluate the efficacy and safety of tirofiban for patients with acute ischemic stroke (AIS), especially posterior circulation stroke (PCS).Methods: We enrolled consecutive patients with AIS who suffered large artery occlusion (LAO) and ...
Lingxin Cai +8 more
doaj +1 more source
Journal of Neurorestoratology, 2022 ObjectiveTo investigate the effectiveness and safety of tirofiban in patients with acute ischemic stroke (AIS) without large-vessel occlusions and not receiving intravenous thrombolysis.MethodsOverall, 267 cases were included in the study (134 cases in ...
Yongpeng Yu +4 more
doaj +1 more source
Platelets, 2022 We aimed to investigate the effects of integrin αIIbβ3 inhibitor tirofiban on hallmarks of platelet activation, degranulation, and aggregation during its use to analyze activated but non-complexed platelets via flow cytometry.
Martina Aguiar Bucsai +4 more
doaj +1 more source